PMV Pharmaceuticals Inc. (PMVP)
PMVP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | PMVP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001699382 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "As a result, management has concluded that there is no longer substantial doubt about the Company's ability to continue as a going concern as of the date of this Quarterly Report." | 10-Q 2026-11-10 |
| Cash and burn | $20.0M cash; operating cash flow -$17.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 75,534,742 (2026-11-10); 53,211,507 a year earlier; 51,157,636 three years earlier. | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-09-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$34.4M | -$18.2M | $20.0M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$18.1M | -$14.6M | $12.5M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2026 2026-03-31 | Not filed | -$18.0M | -$19.7M | $39.1M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2025 2025-12-31 | Not filed | -$18.0M | -$17.2M | $38.0M | No debt tags | Needs four quarters | 10-K 2026-03-06 |
| Q3 2025 2025-09-30 | Not filed | -$21.1M | -$19.8M | $36.3M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$21.2M | -$18.3M | $44.1M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2025 2025-03-31 | Not filed | -$17.4M | -$18.3M | $51.3M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2024 2024-12-31 | Not filed | -$23.0M | -$16.7M | $40.9M | No debt tags | Needs four quarters | 10-K 2026-03-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-02 |
| Latest annual report | 10-K | 2026-03-06 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 393 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.8% |
| 1 month | -5.9% |
| 3 months | +4.5% |
| Year to date | +1.6% |
| 1 year | -6.6% |
| From 52-week high | -29.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RTSN | Retension Pharmaceuticals Inc. | $11.46 | -6.60% | $90.3M |
| ANIX | Anixa Biosciences Inc. | $2.55 | -2.67% | $88.6M |
| NBP | NovaBridge Biosciences | $0.7915 | -6.87% | $91.3M |
| HURA | TuHURA Biosciences Inc. | $1.33 | -4.32% | $87.5M |
| KZIA | Kazia Therapeutics Limited | $5.60 | -15.41% | $87.1M |
| GNLX | Genelux Corporation | $1.92 | +2.95% | $86.9M |
| NKTX | Nkarta Inc. | $1.21 | +1.68% | $86.8M |
| RLYB | Rallybio Corporation | $15.43 | -1.88% | $86.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier